BAYRY:OTO-Bayer AG ADR (Sponsored) (USD)

COMMON STOCK | Drug Manufacturers - General | OTC Pink

Last Closing

USD 7.43

Change

+0.04 (+0.54)%

Market Cap

USD 92.32B

Volume

0.47M

Analyst Target

USD 22.84
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bayer AG is engaged in the development, production and marketing of prescription Pharmaceutical. Its business segments are pharmaceutical, Consumer Health, Crop Science, Animal Health, and Covestro.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-29 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
LLY Eli Lilly and Company

-15.90 (-2.02%)

USD 733.28B
JNJ Johnson & Johnson

+1.61 (+1.05%)

USD 360.64B
MRK Merck & Company Inc

-0.85 (-0.65%)

USD 329.42B
ABBV AbbVie Inc

+0.56 (+0.34%)

USD 289.23B
NVS Novartis AG ADR

-0.53 (-0.51%)

USD 202.14B
AMGN Amgen Inc

-4.32 (-1.35%)

USD 171.14B
PFE Pfizer Inc

+0.10 (+0.35%)

USD 157.25B
GLAXF GSK plc

-0.55 (-2.41%)

USD 92.19B
GSK GlaxoSmithKline PLC ADR

-0.82 (-1.79%)

USD 90.02B
BMY Bristol-Myers Squibb Company

-0.44 (-0.99%)

USD 89.42B

ETFs Containing BAYRY

SMTU:PA 7.18 % 0.00 %

N/A

N/A
SMTU:XETRA 7.18 % 0.00 %

N/A

N/A
INAG 2.93 % 0.00 %

N/A

N/A
TWAR 1.29 % 0.00 %

N/A

N/A
UEFR:F 0.61 % 0.00 %

N/A

N/A
UEFR:XETRA 0.61 % 0.00 %

N/A

N/A
DBGR 0.00 % 0.46 %

N/A

N/A
DXGE 0.00 % 0.48 %

N/A

N/A
EWG iShares MSCI Germany ETF 0.00 % 0.47 %

-0.39 (-1.25%)

USD 0.96B
HEWG iShares Currency Hedged M.. 0.00 % 0.06 %

-0.29 (-1.25%)

USD 0.03B
FLGR Franklin FTSE Germany ETF 0.00 % 0.09 %

-0.21 (-1.25%)

USD 0.02B
IEDL:LSE iShares Edge MSCI Europe .. 0.00 % 0.00 %

-0.02 (-1.25%)

USD 1.50B
IEFV:LSE iShares MSCI Europe Value.. 0.00 % 0.00 %

-2.95 (-1.25%)

USD 1.43B
IEVL:LSE iShares MSCI Europe Value.. 0.00 % 0.00 %

-0.03 (-1.25%)

USD 1.43B
CG1:PA Amundi ETF DAX UCITS ETF .. 0.00 % 0.00 %

-2.55 (-1.25%)

USD 0.66B
DAX:PA Multi Units Luxembourg - .. 0.00 % 0.00 %

-1.34 (-1.25%)

USD 0.66B
MIVU:PA Amundi Index Solutions MS.. 0.00 % 0.00 %

+0.43 (+-1.25%)

USD 0.29B
C001:XETRA Lyxor Core DAX (DR) UCITS.. 0.00 % 0.00 %

-1.20 (-1.25%)

USD 1.06B
C006:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

-0.34 (-1.25%)

USD 0.09B
DBXD:XETRA Xtrackers - DAX UCITS ETF 0.00 % 0.00 %

-1.40 (-1.25%)

USD 4.37B
EL4A:XETRA Deka DAX UCITS ETF 0.00 % 0.00 %

-1.36 (-1.25%)

USD 1.29B
EL4F:XETRA Deka DAX (ausschüttend) .. 0.00 % 0.00 %

-0.61 (-1.25%)

USD 0.83B
MIVU:XETRA Amundi Index Solutions MS.. 0.00 % 0.00 %

+0.46 (+-1.25%)

USD 0.30B
XDDX:XETRA Xtrackers DAX Income UCIT.. 0.00 % 0.00 %

-0.96 (-1.25%)

USD 0.29B
EXS1:XETRA iShares Core DAX® UCITS .. 0.00 % 0.00 %

-1.28 (-1.25%)

USD 6.27B
E909:XETRA Lyxor 1 DAX 50 ESG (DR) U.. 0.00 % 0.00 %

-0.52 (-1.25%)

USD 0.30B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.50% 18% F 7% C-
Dividend Return 0.32% 27% F 17% F
Total Return -19.18% 18% F 7% C-
Trailing 12 Months  
Capital Gain -54.70% 18% F 3% F
Dividend Return 4.03% 73% C 59% D-
Total Return -50.66% 18% F 4% F
Trailing 5 Years  
Capital Gain -55.56% 20% F 9% A-
Dividend Return 15.39% 50% F 59% D-
Total Return -40.17% 20% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain -10.09% 22% F 22% F
Dividend Return -6.08% 19% F 25% F
Total Return 4.02% 66% D+ 63% D
Risk Return Profile  
Volatility (Standard Deviation) 17.85% 75% C 89% A-
Risk Adjusted Return -34.04% 19% F 20% F
Market Capitalization 92.32B 27% F 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.